ME01855B - Jedinjenja benzimidazola - Google Patents
Jedinjenja benzimidazolaInfo
- Publication number
- ME01855B ME01855B MEP-2010-346A MEP34610A ME01855B ME 01855 B ME01855 B ME 01855B ME P34610 A MEP34610 A ME P34610A ME 01855 B ME01855 B ME 01855B
- Authority
- ME
- Montenegro
- Prior art keywords
- group
- solvate
- compound
- methyl
- salt
- Prior art date
Links
- -1 Benzimidazole compound Chemical class 0.000 title claims 5
- 150000001875 compounds Chemical class 0.000 claims 34
- 239000012453 solvate Substances 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 33
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 15
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 10
- 229910052731 fluorine Inorganic materials 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 201000006549 dyspepsia Diseases 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- 230000000069 prophylactic effect Effects 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 208000025865 Ulcer Diseases 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 208000000718 duodenal ulcer Diseases 0.000 claims 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 231100000397 ulcer Toxicity 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims 3
- 201000005917 gastric ulcer Diseases 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- IOTXLNFGBVIKPF-UHFFFAOYSA-N 2-[[3-methyl-4-(1,5,9-trioxaspiro[5.5]undecan-3-ylmethoxy)pyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=C(CS(=O)C=2NC3=CC=CC=C3N=2)N=CC=C1OCC(CO1)COC21CCOCC2 IOTXLNFGBVIKPF-UHFFFAOYSA-N 0.000 claims 2
- JSQBHPGRXGUKOR-UHFFFAOYSA-N 2-[[4-(5,9-dioxaspiro[3.5]nonan-7-yloxy)pyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1S(=O)CC(N=CC=1)=CC=1OC(CO1)COC21CCC2 JSQBHPGRXGUKOR-UHFFFAOYSA-N 0.000 claims 2
- DWDKHTXMLSZGDL-UHFFFAOYSA-N 2-[[4-[(2,2-dimethyl-1,3-dioxan-5-yl)methoxy]-3,5-dimethylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=CN=C(CS(=O)C=2NC3=CC=CC=C3N=2)C(C)=C1OCC1COC(C)(C)OC1 DWDKHTXMLSZGDL-UHFFFAOYSA-N 0.000 claims 2
- 206010002243 Anastomotic ulcer Diseases 0.000 claims 2
- 206010061164 Gastric mucosal lesion Diseases 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims 2
- 239000003899 bactericide agent Substances 0.000 claims 2
- 230000003628 erosive effect Effects 0.000 claims 2
- 201000000052 gastrinoma Diseases 0.000 claims 2
- 208000024798 heartburn Diseases 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- PTGBKPZTLZSJIG-UHFFFAOYSA-N 2-[[3-methyl-4-[(8-methyl-1,4,7,9-tetraoxaspiro[4.5]decan-8-yl)methoxy]pyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=C(CS(=O)C=2NC3=CC=CC=C3N=2)N=CC=C1OCC(OC1)(C)OCC21OCCO2 PTGBKPZTLZSJIG-UHFFFAOYSA-N 0.000 claims 1
- YZYQTWILJMJUBX-UHFFFAOYSA-N 2-[[3-methyl-4-[2-(8-methyl-1,4,7,9-tetraoxaspiro[4.5]decan-8-yl)ethoxy]pyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=C(CS(=O)C=2NC3=CC=CC=C3N=2)N=CC=C1OCCC(OC1)(C)OCC21OCCO2 YZYQTWILJMJUBX-UHFFFAOYSA-N 0.000 claims 1
- AZGVKNPVQMGIHS-UHFFFAOYSA-N 2-[[4-(1,3-dioxolan-4-ylmethoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=C(CS(=O)C=2NC3=CC=CC=C3N=2)N=CC=C1OCC1COCO1 AZGVKNPVQMGIHS-UHFFFAOYSA-N 0.000 claims 1
- MKGXSTCRHKKBDO-UHFFFAOYSA-N 2-[[4-(5,7-dioxaspiro[2.5]octan-6-ylmethoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=C(CS(=O)C=2NC3=CC=CC=C3N=2)N=CC=C1OCC(OC1)OCC21CC2 MKGXSTCRHKKBDO-UHFFFAOYSA-N 0.000 claims 1
- FBBJHLVGYGVBLE-UHFFFAOYSA-N 2-[[4-(5,9-dioxaspiro[3.5]nonan-7-yloxy)-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=C(CS(=O)C=2NC3=CC=CC=C3N=2)N=CC=C1OC(CO1)COC21CCC2 FBBJHLVGYGVBLE-UHFFFAOYSA-N 0.000 claims 1
- XPSQFXMHDZHDFH-UHFFFAOYSA-N 2-[[4-[(5,5-dimethyl-1,3-dioxan-2-yl)methoxy]-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=C(CS(=O)C=2NC3=CC=CC=C3N=2)N=CC=C1OCC1OCC(C)(C)CO1 XPSQFXMHDZHDFH-UHFFFAOYSA-N 0.000 claims 1
- JJBNJMLZSQXVQV-UHFFFAOYSA-N 2-[[4-[2-(8-ethyl-1,4,7,9-tetraoxaspiro[4.5]decan-8-yl)ethoxy]-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound C1OC(CC)(CCOC=2C(=C(CS(=O)C=3NC4=CC=CC=C4N=3)N=CC=2)C)OCC21OCCO2 JJBNJMLZSQXVQV-UHFFFAOYSA-N 0.000 claims 1
- NSZDOQZLRNHVPY-UHFFFAOYSA-N 2-[[4-[[2,2-bis(fluoromethyl)-1,3-dioxan-5-yl]methoxy]-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound C1=CN=C(CS(=O)C=2NC3=CC=CC=C3N=2)C(C)=C1OCC1COC(CF)(CF)OC1 NSZDOQZLRNHVPY-UHFFFAOYSA-N 0.000 claims 1
- 206010000087 Abdominal pain upper Diseases 0.000 claims 1
- 208000000884 Airway Obstruction Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023665 Barrett oesophagus Diseases 0.000 claims 1
- 206010008589 Choking Diseases 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical group F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims 1
- 206010017788 Gastric haemorrhage Diseases 0.000 claims 1
- 206010017865 Gastritis erosive Diseases 0.000 claims 1
- 206010017866 Gastritis haemorrhagic Diseases 0.000 claims 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010020601 Hyperchlorhydria Diseases 0.000 claims 1
- 206010021518 Impaired gastric emptying Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 206010067171 Regurgitation Diseases 0.000 claims 1
- 206010042220 Stress ulcer Diseases 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 206010006514 bruxism Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 230000027119 gastric acid secretion Effects 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 claims 1
- 208000001288 gastroparesis Diseases 0.000 claims 1
- 229940037467 helicobacter pylori Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000024981 pyrosis Diseases 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001738 temporomandibular joint Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (41)
1. Jedinjenje predstavljeno formulom: [Formula l] u kojoj: R1 i R3 mogu biti isti ili različiti i svaki predstavlja atom vodonika ili C1-C6 alkil grupu; R2 je grupa, predstavljena sa: [Formula 2] gde W2 predstavlja: atom vodonika, C1-C6 alkil grupu ili atom halogena (pod uslovom da pojavljivanja W2 na benzenskom prstenu može biti 1 do 3, i mogu biti isti ili različiti); n1 predstavlja 1 do 5, n2 predstavlja 1 do 4, a n3 predstavlja 1 do 6. navedena grupa opciono ima 1 do 4 grupe odabrane od grupe A1, koja se sastoji od: atoma halogena, C1-C6 alkil grupe, C1-C6 alkoksi grupe, C1-C6 haloalkil grupe, C1-C6 alkoksi C1-C6 alkil grupe i hidroksilne grupe; R1, R2, R6 i R7 mogu biti isti ili različiti, a svaki predstavlja: atom vodonika, hidroksilnu grupu, halogeni atom, C1-C6 alkil grupu, C1-C6 haloalkil grupu, C1-C6 alkoksi grupu ili C1-C6 haloalkoksi grupu, ili kombinacija R2 i R6 predstavlja metilendioksi grupu ili etilendioksi grupu; i W1 predstavlja pojedinačnu jednostruku vezu ili ravnolančanu ili razgranatu alkilensku grupu koja ima 1 do 8 ugljenikovih atoma.
2. Jedinjenje ili njegova so, ili njihov solvat, kao u patentnom zahtevu 1, pri čemu je R1 atom vodonika ili metil grupa.
3. Jedinjenje ili njegova so, ili njihov solvat, kao u patentnom zahtevu 1, pri čemu je R1 metil grupa.
4. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 3, pri čemu je R2 grupa predstavljena sa: [Formula 3] gde W2 predstavlja: atom vodonika, C1-C6 alkil grupu ili atom halogena (pod uslovom da pojavljivanja W2 na benzenskom prstenu može biti 1 do 3, i mogu biti isti ili različiti); n1 predstavlja 1 do 5, n2 predstavlja 1 do 4, a n3 predstavlja 1 do 6. navedena grupa opciono ima 1 do 2 grupe odabrane od grupe A2, koja se sastoji od: atoma fluorida, metil grupe, etil grupe, propil grupe, metoksi grupe i monofluorometil grupe. 5
5. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 3, pri čemu je R2 grupa predstavljena sa formulom (4): [Formula 4]
6. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 3, pri čemu je R2 grupa predstavljena sa [Formula 5]
7. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 6, pri čemu je R3 atom vodonika ili metil grupa.
8. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 6, pri čemu je R3 metil grupa.
9. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 8, pri čemu je R4 atom vodonika, hidroksilna grupa, metil grupa, etil grupa, metoksi grupa, etoksi grupa ili atom fluora.
10. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 8, pri čemu je R4 atom vodonika, metil grupa ili atom fluora.
11. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 8, pri čemu je R4 atom vodonika.
12. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 11, pri čemu je R5 atom vodonika, hidroksilna grupa, metil grupa, etil grupa, metoksi grupa, etoksi grupa ili atom fluora.
13. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 11, pri čemu je R5 atom vodonika, metil grupa ili atom fluora.
14. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 11, pri čemu je R5 atom vodonika.
15. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 14, pri čemu je R6 atom vodonika, hidroksilna grupa, metil grupa, etil grupa, metoksi grupa, etoksi grupa ili atom fluora.
16. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 14, pri čemu je R6 atom vodonika, metil grupa ili atom fluora.
17. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 14, pri čemu je R6 atom vodonika.
18. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 17, pri čemu je R7 atom vodonika, hidroksilna grupa, metil grupa, etil grupa, metoksi grupa, etoksi grupa ili atom fluora.
19. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 17, pri čemu je R7 atom vodonika, metil grupa ili atom fluora.
20. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 17, pri čemu je R7 atom vodonika.
21. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 20, pri čemu je W1 jednostruka veza, metilenska grupa ili etilenska grupa..
22. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 20, pri čemu je W1 metilenska grupa.
23. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 4, pri čemu su sva pojavljivanja W2 atomi vodonika.
24. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 4, pri čemu n1 je 1 do 3.
25. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 4, pri čemu n1 je 1 ili 2.
26. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 4, pri čemu n2 je 1 ili 3.
27. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 4, pri čemu n3 je 1 do 4.
28. Jedinjenje ili njegova so, ili njihov solvat, kao u ma kom od patentnih zahteva 1 do 4, pri čemu n3 je 1 ili 2.
29. Jedinjenje ili njegova so, ili njihov solvat, kao u patentnom zahtevu 1, pri čemu je jedinjenje odabrano iz sledeće grupe, koja se sastoji od: 2-(((4-((5, 5-dimetil-1, 3-dioksan-2-il)metoksi)-3-metilpiridin-2-il)metil)sulfinil)-1H- benzimidazola; 2-(((4-(5, 7-dioksaspiro[2. 5]okt-6-ilmetoksi)-3-metilpiridin-2-il)metil)sulfinil)-1H- benzimidazola; 2-(((3-metil-4-(1, 5, 9-trioksaspiro[5. 5]undec-3-ilmetoksi)piridin-2-il)metil)sulfinil)-1H- benzimidazola; 2-(((4-((2, 2-dimetil-1, 3-dioksan-5-il)metoksi)-3, 5-dimetilpiridin-2-il)metil)sulfinil)-1H- benzimidazola; 2-(((3-metil-4-(2-(8-metil-1, 4, 7, 9-tetraoksaspiro[4. 5]dec-8-il)etoksi)piridin-2-il)metil) sulfinil)-1 H-benzimidazola; 2-(((4-(5, 9-dioksaspiro[3. 5]non-7-iloksi)piridin-2-il)metil)sulfinil)-1 H-benzimidazola; 2-(((4-(2-(8-etil-1, 4, 7, 9-tetraoksaspiro[4. 5]dec-8-il)etoksi)-3-metilpiridin-2-il)metil) sulfinil)-1 H-benzimidazola; 2-(((4-(1, 3-dioksolan-4-ilmetoksi)-3-metilpiridin-2-il)metil)sulfinil)-1 H-benzimidazola; 2-(((4-((2, 2-bis(fluorometil)-1, 3-dioksan-5-il)metoksi)-3-metilpiridin-2-il)metil)sulfinil)-1H- benzimidazola; 2-(((4-(5, 9-dioksaspiro[3. 5]non-7-iloksi)-3-metilpiridin-2-il)metil)sulfinil)-1 H-benzimidazola; 2-(((4-((2-metoksi-1, 3-dioksan-5-ii)metoksi)-3-metilpiridin-2-i! )metil)sulfinil)-1 H-benzimidazola; 2-(((3-metil-4-((8-metil-1, 4, 7, 9-tetraoksaspiro[4. 5]dec-8-il)metoksi)piridin-2-il)metil) sulfinil)-1 H-benzimidazola; 2-(((4-(5, 9-dioksaspiro[3. 5]non-7-iloksi)piridin-2-il)metil)sulfinil)-1H-benzimidazola; i 2-(((4-((5, 5-difluoro-1, 3-dioksan-2-il)metoksi)-3-metilpiridin-2-il)metil)sulfinil)-1 H-benzimidazola.
30. 2-(((4-((5, 5-dimetil-1, 3-dioksan-2-il)metoksi)-3-metilpiridin-2-il)metil)sulfinil)-1 H-benzimidazol ili njegova so, iii njihov solvat.
31. 2-(((4-(5, 7-dioksaspiro[2. 5]okt-6-iimetoksi)-3-metilpiridin-2-il)metil)sulfinil)-1H-benzimidazol ili njegova so, ili njihov solvat.
32. 2-(((3-metiI-4-(1, 5, 9-trioksaspiro[5. 5]undec-3-ilmetoksi)piridin-2-il)metil)sulfinil)-1H-benzimidazol ili njegova so, ili njihov solvat.
33. 2-(((4-((2, 2-dimetil-1, 3-dioksan-5-il)metoksi)-3, 5-dimetilpiridin-2-il)metil)su! finil)-1H-benzimidazol ili njegova so, ili njihov solvat.
34. Lek, koji sadrži jedinjenje ili njegovu so ili njihov solvat u skladu sa ma kojim od patentnih zahteva 1 do 33.
35. Inhibitor sekrecije želudačne kiseline, koji obuhvata jedinjenje ili njegovu so ili njihov solvat u skladu sa ma kojim od patentnih zahteva 1 do 33.
36. Terapeutsko sredstvo ili profilaktičko sredstvo za bolesti ili simptome koji su povezani sa kiselinom, koje obuhvata jedinjenje ili njegovu so ili njihov solvat u skladu sa ma kojim od patentnih zahteva 1 do 33.
37. Terapeutsko sredstvo ili profilaktičko sredstvo, kao u patentnom zahtvu 36, pri čemu su bolesti ili simptomi, koji su u vezi sa kiselinom: čir na želucu, čir na dvanaestopalačnom crevu, anastomozni čir, gastroezofagusna refluksna bolest, Zollinger-Ellison sindrom, simptomatska gastroezofagusna refluksna bolest, endoskopski negativna bolest gastroezofagusnog refluksa, ne-erozivna gastroezofagusna refluksna bolest, gastroezofagusna regurgitacija, NUD (ne-ulcerska dispepsija), abnormalni osećaj u grlu, Barrettov ezofagus, NSAID-om indukovani čir, gastritis, želudačano krvarenje, hemoragični gastritis, gastrointestinalno krvarenje, peptični čir, krvareći čir, stresni čir, želudačnii hiperaciditet, dispepsija, gastropareza, čir kod starijih ljudi, tvrdokorni čir, akutna želudačana mukozna lezija, žgaravica, piroza sindroma apneje pri spavanju, škrgutanje zubima, gastralgija, osećaj težine u stomaku, zagrcavanje, mučnina, artroza temporomandibularnog zgloba ili erozivni gastritis,
38. Terapeutsko sredstvo ili profilaktičko sredstvo, kao u patentnom zahtvu 36, pri čemu su bolesti ili simptomi, koje su u vezi sa kiselinom: čir na želucu, čir na dvanaestopalačnom crevu, anastomozni čir, gastroezofagusna refluksna bolest, Zollinger-Ellison sindrom, simptomatska gastroezofagusna refluksna bolest, endoskopski negativna bolest gastroezofagusnog refluksa, ne-erozivna gastroezofagusna refluksna bolest ili akutna želudačana mukozna lezija.
39. Terapeutsko sredstvo ili profilaktičko sredstvo, kao u patentnom zahtvu 36, pri čemu su bolesti ili simptomi: bolest gastroezofagusnog refluksa ili simptomatska bolest gastroezofagusnog refluksa.
40. Terapeutsko sredstvo ili profilaktičko sredstvo, kao u patentnom zahtvu 36, pri čemu su bolesti, koje su u vezi sa kiselinom, želudačni ulcer ili ulcer na dvanaestopalačnom crevu.
41. Baktericidni agens ili pomoćno baktericidno sredstvo protiv Helicobacter pylori u želucu, koji obuhvata jedinjenje ili njegovu so ili njihov solvat, u skladu sa ma kojim od patentnih zahteva 1 do 33.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005117643 | 2005-04-15 | ||
| US67584805P | 2005-04-29 | 2005-04-29 | |
| EP06731998A EP1870409B1 (en) | 2005-04-15 | 2006-04-17 | Benzimidazole compounds |
| PCT/JP2006/308069 WO2006112442A1 (ja) | 2005-04-15 | 2006-04-17 | ベンズイミダゾール化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01855B true ME01855B (me) | 2011-02-28 |
Family
ID=37115157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2010-346A ME01855B (me) | 2005-04-15 | 2006-04-17 | Jedinjenja benzimidazola |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20070015782A1 (me) |
| EP (1) | EP1870409B1 (me) |
| JP (1) | JP4949246B2 (me) |
| KR (1) | KR101285696B1 (me) |
| AU (1) | AU2006237974B2 (me) |
| BR (1) | BRPI0608400B8 (me) |
| CA (1) | CA2602610C (me) |
| CY (1) | CY1110074T1 (me) |
| DE (1) | DE602006014261D1 (me) |
| DK (1) | DK1870409T3 (me) |
| ES (1) | ES2344467T3 (me) |
| HR (1) | HRP20100389T1 (me) |
| IL (1) | IL186282A (me) |
| ME (1) | ME01855B (me) |
| NO (1) | NO339502B1 (me) |
| NZ (1) | NZ561920A (me) |
| PL (1) | PL1870409T3 (me) |
| PT (1) | PT1870409E (me) |
| RS (1) | RS51389B (me) |
| RU (1) | RU2409573C2 (me) |
| SI (1) | SI1870409T1 (me) |
| WO (1) | WO2006112442A1 (me) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070015782A1 (en) * | 2005-04-15 | 2007-01-18 | Eisai Co., Ltd. | Benzimidazole compound |
| WO2007122686A1 (ja) * | 2006-04-14 | 2007-11-01 | Eisai R & D Management Co., Ltd. | ベンズイミダゾール化合物 |
| WO2008047681A1 (en) * | 2006-10-13 | 2008-04-24 | Eisai R & D Management Co., Ltd. | Benzimidazole compound having gastric acid secretion inhibitory activity |
| JP2009196894A (ja) * | 2006-10-13 | 2009-09-03 | Eisai R & D Management Co Ltd | スルフィニルベンズイミダゾール化合物またはその塩の製造方法 |
| TWI546306B (zh) * | 2007-04-11 | 2016-08-21 | 第一三共股份有限公司 | 神經胺酸衍生物之製造方法 |
| SI2071986T1 (sl) * | 2007-12-18 | 2012-04-30 | Nestec Sa | Sistem za pripravo napitka iz sestavin, podprt s kodiranim vloĹľkom |
| EP2588467A1 (en) | 2010-07-01 | 2013-05-08 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
| CN103958480B (zh) | 2012-09-04 | 2016-04-06 | 上海恒瑞医药有限公司 | 咪唑啉类衍生物、其制备方法及其在医药上的应用 |
| EP2803666B1 (de) * | 2013-05-17 | 2016-04-27 | Symrise AG | Cyclische Acetale und Ketale sowie deren Verwendung als Riechstoff |
| JP6377334B2 (ja) * | 2013-10-25 | 2018-08-22 | 東洋鋼鈑株式会社 | 非線形光学色素、フォトリフラクティブ材料組成物、フォトリフラクティブ基材およびホログラム記録媒体 |
| CN107428726B (zh) * | 2014-12-26 | 2021-03-16 | 国立大学法人东京大学 | 光学活性的质子泵抑制剂化合物的制备方法 |
| US10544113B2 (en) | 2016-03-07 | 2020-01-28 | National Health Research Institute | Thiazolidinone compounds and use thereof |
| CN112457175B (zh) * | 2020-11-03 | 2022-09-02 | 山东师范大学 | 一种制备1,3-二苄氧基-2-丙酮的方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8300736D0 (sv) * | 1983-02-11 | 1983-02-11 | Haessle Ab | Novel pharmacologically active compounds |
| DK585485A (da) | 1984-12-18 | 1986-08-08 | Utsuka Pharm Co Ltd | Tetrahydroquinolinderivat, imidazopyridinderivat, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat med mindst en saadan forbindelse |
| JPS62277322A (ja) | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
| JPS62207271A (ja) | 1986-03-06 | 1987-09-11 | Yamanouchi Pharmaceut Co Ltd | ２−ピリジルメチルチオ基または２−ピリジルメチルスルフイニル基で置換された縮合環化合物 |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| JPH0643426B2 (ja) | 1986-07-25 | 1994-06-08 | 東京田辺製薬株式会社 | イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤 |
| US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
| JPH0222273A (ja) * | 1987-07-21 | 1990-01-25 | Yoshitomi Pharmaceut Ind Ltd | ピリジン化合物およびその医薬用途 |
| JPH0633261B2 (ja) | 1988-01-22 | 1994-05-02 | 東京田辺製薬株式会社 | 新規なイミダゾ［４，５−ｂピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤 |
| AU649456B2 (en) * | 1990-06-20 | 1994-05-26 | Astra Aktiebolag | Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use |
| SE9002206D0 (sv) * | 1990-06-20 | 1990-06-20 | Haessle Ab | New compounds |
| JP2820829B2 (ja) | 1991-03-07 | 1998-11-05 | 武田薬品工業株式会社 | 有核散剤およびその製造方法 |
| JPH05117268A (ja) * | 1991-10-22 | 1993-05-14 | Yoshitomi Pharmaceut Ind Ltd | ピリジン化合物 |
| JPH05177268A (ja) | 1992-01-09 | 1993-07-20 | Amada Co Ltd | 縦型パンチプレス |
| CA2218493C (en) * | 1995-04-21 | 2005-02-22 | Neurosearch A/S | Benzimidazole compounds and their use as modulators of the gabaa receptor complex |
| WO1999053905A1 (fr) | 1998-04-17 | 1999-10-28 | Taisho Pharmaceutical Co., Ltd. | Comprimes a liberation prolongee a unites multiples |
| HRP20010106A2 (en) | 1998-08-10 | 2002-02-28 | Partnership Of Michael E Garst | Prodrugs of proton pump inhibitors |
| TW404832B (en) | 1999-01-27 | 2000-09-11 | Nang Kuang Pharmaceutical Co L | The oral medicine with good stability cotaining the omeprazole or the analogues |
| CA2362930C (en) | 1999-02-26 | 2010-10-05 | Nitromed, Inc. | Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use |
| US6852739B1 (en) * | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
| ES2168043B1 (es) | 1999-09-13 | 2003-04-01 | Esteve Labor Dr | Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido. |
| AU2001296908A1 (en) | 2000-09-29 | 2002-04-08 | Geneva Pharmaceuticals, Inc. | Proton pump inhibitor formulation |
| JP4331930B2 (ja) | 2001-10-17 | 2009-09-16 | 武田薬品工業株式会社 | 酸に不安定な薬物の高含量顆粒 |
| ES2392960T3 (es) | 2001-10-17 | 2012-12-17 | Takeda Pharmaceutical Company Limited | Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido |
| JP2003137771A (ja) | 2001-10-30 | 2003-05-14 | Nichiko Pharmaceutical Co Ltd | 難溶性薬物用医薬製剤 |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
| WO2004066924A2 (en) | 2003-01-24 | 2004-08-12 | Andrx Labs Llc | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
| WO2004080439A1 (ja) | 2003-03-12 | 2004-09-23 | Takeda Pharmaceutical Company Limited | 高濃度に活性成分を球形核に付着させた医薬組成物 |
| EP1652514A1 (en) | 2003-08-04 | 2006-05-03 | Eisai Co., Ltd. | At-use dispersed preparation |
| US20070015782A1 (en) * | 2005-04-15 | 2007-01-18 | Eisai Co., Ltd. | Benzimidazole compound |
-
2006
- 2006-04-14 US US11/403,815 patent/US20070015782A1/en not_active Abandoned
- 2006-04-17 JP JP2007528143A patent/JP4949246B2/ja not_active Expired - Fee Related
- 2006-04-17 PT PT06731998T patent/PT1870409E/pt unknown
- 2006-04-17 RS RSP-2010/0346A patent/RS51389B/sr unknown
- 2006-04-17 AU AU2006237974A patent/AU2006237974B2/en not_active Ceased
- 2006-04-17 SI SI200630712T patent/SI1870409T1/sl unknown
- 2006-04-17 DE DE602006014261T patent/DE602006014261D1/de active Active
- 2006-04-17 ME MEP-2010-346A patent/ME01855B/me unknown
- 2006-04-17 ES ES06731998T patent/ES2344467T3/es active Active
- 2006-04-17 WO PCT/JP2006/308069 patent/WO2006112442A1/ja not_active Ceased
- 2006-04-17 BR BRPI0608400A patent/BRPI0608400B8/pt not_active IP Right Cessation
- 2006-04-17 RU RU2007138053/04A patent/RU2409573C2/ru active
- 2006-04-17 EP EP06731998A patent/EP1870409B1/en active Active
- 2006-04-17 HR HR20100389T patent/HRP20100389T1/hr unknown
- 2006-04-17 PL PL06731998T patent/PL1870409T3/pl unknown
- 2006-04-17 NZ NZ561920A patent/NZ561920A/en not_active IP Right Cessation
- 2006-04-17 KR KR1020077023561A patent/KR101285696B1/ko not_active Expired - Fee Related
- 2006-04-17 DK DK06731998.8T patent/DK1870409T3/da active
- 2006-04-17 CA CA2602610A patent/CA2602610C/en active Active
- 2006-09-14 US US11/520,838 patent/US7425634B2/en active Active
-
2007
- 2007-09-25 IL IL186282A patent/IL186282A/en active IP Right Grant
- 2007-11-15 NO NO20075904A patent/NO339502B1/no not_active IP Right Cessation
-
2008
- 2008-08-11 US US12/189,590 patent/US8124780B2/en not_active Expired - Fee Related
-
2010
- 2010-06-11 CY CY20101100543T patent/CY1110074T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01855B (me) | Jedinjenja benzimidazola | |
| AU2003226211B2 (en) | Substituted benzazoles and use thereof as RAF kinase inhibitors | |
| PE20081475A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| JP2012528166A5 (me) | ||
| JP2009520017A5 (me) | ||
| ATE512969T1 (de) | Benzimidazolderivate als selektive säurepumpenhemmer | |
| TW200732326A (en) | Chromane substituted benzimidazole derivatives | |
| FI4148050T3 (fi) | Uusi haponerityksen estäjä ja sen käyttö | |
| ME01598B (me) | Jedinjenja pirola | |
| EA003697B1 (ru) | Дизамещенные бициклические гетероциклы, их получение и применение в качестве лекарственных средств | |
| RU2007105970A (ru) | Пиперидиновые производные в качестве лигандов гистаминового из рецептора | |
| JP2016505536A5 (me) | ||
| RU2015122126A (ru) | Производное пиррол сульфонамида, метод его получения и применение в медицине | |
| CA2672373A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| AR051172A1 (es) | Compuestos derivados de acido tartarico para el tratamiento de desordenes inflamatorios. composiciones farmaceuticas | |
| RU2002133863A (ru) | Производные замещенного пирролопиридинона, пригодные в качестве ингибиторов фосфодиэстеразы | |
| JP3741120B2 (ja) | Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 | |
| RU2013154117A (ru) | Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы | |
| JP2019524691A (ja) | イミダゾ［１，２−ａ］ピリジン誘導体、その製造方法及びその用途 | |
| AR074819A1 (es) | Compuestos heterociclicos antivirales | |
| JP2005539013A (ja) | ニトロソ化プロトンポンプ阻害剤、組成物および使用方法 | |
| JP2008524249A5 (me) | ||
| RU2139286C1 (ru) | Замещенные арилалкилтиоалкилтиопиридины для борьбы с бактериями helicobacter | |
| ATE442140T1 (de) | Chroman-substituierte benzimidazolderivate als säurepumpenantagonisten | |
| PE20081683A1 (es) | Nuevos derivados de sulfonamida |